Genomic characterization of first line advanced or metastatic non-small cell lung cancer (aNSCLC) patients (pts) subgroups associated with good/bad prognosis

Development of new therapies for lung cancer treatment has improved survival rates in aNSCLC pts. Certain pts subgroups do not benefit from these treatments and there is lacking evidence on why these show different survival outcomes. We aimed to identify an association between non-driver mutational patterns and pts subgroups of special interest.